Analysis: Unichem Laboratories Limited

Growth thesis

Unichem Laboratories is an Indian pharma company with domestic formulations (60% of business), US/UK generics, API manufacturing, and OTC products. Key growth drivers include 15%+ domestic growth from chronic share gains, 20-30% US growth via 2-3 ANDA launches/year, and OTC expansion with Unienzyme and 3-4 GI products. Rs 300 cr capex on Kolhapur API (90% captive for US filings) and Goa plant aims to boost operating leverage, but timelines for API commercialization (Q1 FY18) and margin expansion (100-150 bps/year) remain delayed. Management has consistently overpromised US sales ($50m+ targets vs. $19.3m H1 FY17) and capex execution, with EBITDA margins flat at ~11% despite repeated guidance.

Why is Unichem Laboratories Limited stock rising?

• Expect to maintain good growth trajectory for next 3-4 quarters driven by chronic portfolio and strategic realignment
• Chronic business expected to continue double-digit growth as it is growing at double the market rate
• US formulations business expected to maintain 20-30% growth rate in coming quarters
• Niche Generics UK subsidiary expected to maintain profitability and topline; new product launches with expanded capacity to add growth
• OTC for Unienzyme shows positive early traction; additional OTC products in development expected in 3-4 quarters

Research report

companyname: Unichem Laboratories Limited ticker: UNICHEMLAB sector: Pharmaceuticals / Generic Drug Manufacturing Unichem Laboratories is an Indian pharmaceutical company that manufactures and sells generic formulations and active pharmaceutical ingredients (APIs). It was incorporated in August 1962 and has operations in 71 countries. As of FY2025, it employs 3,327 people. The company became a subsidiary of Ipca Laboratories Limited in FY2024. Unichem's business is overwhelmingly export-orient...

Catalysts

capex, margin expansion, new product segment, geographic expansion

Growth guidance

No guidance

Management consistency

mixed